Literature DB >> 24691053

TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.

Helena Pópulo1, Paula Boaventura1, João Vinagre2, Rui Batista1, Adélia Mendes1, Regina Caldas3, Joana Pardal4, Filomena Azevedo5, Mrinalini Honavar6, Isabel Guimarães7, José Manuel Lopes8, Manuel Sobrinho-Simões8, Paula Soares9.   

Abstract

The reactivation or reexpression of telomerase (TERT) is a widespread feature of neoplasms. TERT promoter mutations were recently reported that were hypothesized to result from UV radiation. In this retrospective study, we assessed TERT promoter mutations in 196 cutaneous basal cell carcinomas (BCCs), including 102 tumors from X-irradiated patients, 94 tumors from patients never exposed to ionizing radiation treatment, and 116 melanomas. We sought to evaluate the effects of UV and X-ray irradiation on TERT mutation frequency. TERT mutations were detected in 27% of BCCs from X-irradiated patients, 51% of BCCs from nonirradiated patients, and 22% of melanoma patients. TERT mutations were significantly increased in non-X-irradiated BCC patients compared with X-irradiated BCC patients; the mutations also presented a different mutation signature. In nonirradiated patients, TERT mutations were more frequent in BCCs of sun-exposed skin, supporting a possible causative role of UV radiation. In melanoma, TERT promoter mutations were generally restricted to intermittent sun-exposed areas and were associated with nodular and superficial spreading subtypes, increased thickness, ulceration, increased mitotic rate, and BRAFV600E mutations. Our results suggest that various carcinogenic factors may cause distinct TERT promoter mutations in BCC and that TERT promoter mutations might be associated with a poorer prognosis in melanoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691053     DOI: 10.1038/jid.2014.163

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  46 in total

1.  Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.

Authors:  Nancy E Thomas; Sharon N Edmiston; Yihsuan S Tsai; Joel S Parker; Paul B Googe; Klaus J Busam; Glynis A Scott; Daniel C Zedek; Eloise A Parrish; Honglin Hao; Nathaniel A Slater; Michelle V Pearlstein; Jill S Frank; Pei Fen Kuan; David W Ollila; Kathleen Conway
Journal:  Am J Dermatopathol       Date:  2019-04       Impact factor: 1.533

2.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.

Authors:  Dong-Sheng Huang; Zhaohui Wang; Xu-Jun He; Bill H Diplas; Rui Yang; Patrick J Killela; Qun Meng; Zai-Yuan Ye; Wei Wang; Xiao-Ting Jiang; Li Xu; Xiang-Lei He; Zhong-Sheng Zhao; Wen-Juan Xu; Hui-Ju Wang; Ying-Yu Ma; Ying-Jie Xia; Li Li; Ru-Xuan Zhang; Tao Jin; Zhong-Kuo Zhao; Ji Xu; Sheng Yu; Fang Wu; Junbo Liang; Sizhen Wang; Yuchen Jiao; Hai Yan; Hou-Quan Tao
Journal:  Eur J Cancer       Date:  2015-04-02       Impact factor: 9.162

Review 3.  Familial risk of melanoma and links with other cancers.

Authors:  Kachiu C Lee; H William Higgins; Abrar A Qureshi
Journal:  Melanoma Manag       Date:  2015-02-25

4.  Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma.

Authors:  Farshid Fathi; Batool Zamani; Ahmad Piroozmand; Samaneh Mozafarpoor; Effat Seyedhashemi; Reza ArefNezhad; Hossein Motedayyen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

5.  TERT promoter mutations in melanoma survival.

Authors:  Eduardo Nagore; Barbara Heidenreich; Sívaramakrishna Rachakonda; Zaida Garcia-Casado; Celia Requena; Virtudes Soriano; Christoph Frank; Victor Traves; Esther Quecedo; Josefa Sanjuan-Gimenez; Kari Hemminki; Maria Teresa Landi; Rajiv Kumar
Journal:  Int J Cancer       Date:  2016-03-02       Impact factor: 7.396

Review 6.  Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Authors:  João Vinagre; Vasco Pinto; Ricardo Celestino; Marta Reis; Helena Pópulo; Paula Boaventura; Miguel Melo; Telmo Catarino; Jorge Lima; José Manuel Lopes; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

Review 7.  Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling.

Authors:  Efthymia Soura; Philip J Eliades; Kristen Shannon; Alexander J Stratigos; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2016-03       Impact factor: 11.527

8.  Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.

Authors:  Elisabetta Macerola; Barbara Loggini; Riccardo Giannini; Giulia Garavello; Mirella Giordano; Agnese Proietti; Cristina Niccoli; Fulvio Basolo; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2015-06-09       Impact factor: 4.064

Review 9.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

Review 10.  Revisiting determinants of prognosis in cutaneous melanoma.

Authors:  Sarah A Weiss; Douglas Hanniford; Eva Hernando; Iman Osman
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.